1[2]Dubertret L, Murrieta Aguttes M, Tonet J. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study[J]. J Eur Acad Dermatol Venereol, 1999, 12(1): 16-24.
2[3]Rosenzweig P, Caplain H, Chanfour S, et al. Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers[J]. Br J Clin Pharmacol,1995, 40(5): 459-465.
3[1]Prakash A, Lamb HM. Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria[J]. Biodrug, 1998, 10(10): 42-59.
4Greaves M. Chronic urticaria[J]. J Allergy Clin Immunol, 2000,105(4): 664-672.
5Finlay AY, Khan GK.Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use [J]. Clin Exp Dermatol, 1994, 19(3): 210-216.
6McClellan K, Jarvis B. Desloratacline[J]. Drugs, 2001, 61(6):789-796.
7Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine[J].J Allergy Clin Immunol, 2001, 107(4): 751-762.
8Ring J, Hein R,Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria:a randomized, double-blind, placebo-controlled study[J].Int J Dermatol, 2001, 40(1): 72-76.
9Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial[J]. J Am Acad Dermatol, 2003, 48(4): 535-541.
10Zegarska B,Lelinska A,Tyrakowski T.Clinical and experimental aspects of cutaneous neurogenic inflammation[J].Pharmacol Rep,2006,58(1):13-21.
2Augustin M,Ehrle S.Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients[J]. J Eur Acad Dermatol Venereol, 2009,23(3): 292-299.
